<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180465</url>
  </required_header>
  <id_info>
    <org_study_id>LIPO-102-CL-09</org_study_id>
    <secondary_id>LIPO-102-CL-09</secondary_id>
    <nct_id>NCT01180465</nct_id>
  </id_info>
  <brief_title>A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity</brief_title>
  <official_title>A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neothetics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neothetics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LIPO-102 is under evaluation for treatment of abdominal adiposity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>8 weeks treatment and 1 week follow up</time_frame>
    <description>physical exam, ECG, vital signs, clinical assessment is injection site, clinical laboratory tests, and adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in abdominal circumference</measure>
    <time_frame>8 weeks</time_frame>
    <description>abdominal circumference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>photographic assessment</measure>
    <time_frame>8 weeks</time_frame>
    <description>abdominal circumference and volume reduction assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal subcutaneous adiposity questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patient reported outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and clinician photo numeric scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>patient and physician reports of change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment of severity scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>patient reports of change in severity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Weight</condition>
  <arm_group>
    <arm_group_label>LIPO-102 High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-102, Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO-102; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIPO-102</intervention_name>
    <description>LIPO-102 High dose</description>
    <arm_group_label>LIPO-102 High</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIPO-102 Low</intervention_name>
    <description>LIPO-102 Low dose</description>
    <arm_group_label>LIPO-102, Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIPO-102, Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>LIPO-102; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 50 years old inclusive

          -  Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or
             C-PNS

          -  BMI &lt; 25kg/m sq

          -  Stable diet and exercise and body weight

        Exclusion Criteria:

          -  Prior treatment of abdominal subcutaneous adipose tissue

          -  Females within 12 months postpardum

          -  Known hypersensitivity to the drugs or components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <disposition_first_submitted>March 5, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 5, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 26, 2015</disposition_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of abdominal adiposity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

